SOURCE: InoLife Technologies, Inc.

August 19, 2010 08:30 ET

InoLife Technologies, Inc. Engages Continental Investment Group, Inc. for Business Development and Investment Consulting

InoLife Is Poised for Growth in Explosive Genetic Testing Markets

RALEIGH, NC--(Marketwire - August 19, 2010) - InoLife Technologies, Inc. (OTCBB: INOL), a service based healthcare products development, integration and marketing company, announced today it has engaged Continental Investment Group, Inc. to assist in accessing the capital markets as well as targeting specific industries and business development opportunities.

Continental has over 75 years in combined senior management experience in mergers and acquisitions and investment expertise. Continental is a leading expert in capital markets and perpetuating meaningful growth. In addition to advising clients, Continental's principals have unique experiences with M&A, divestitures and corporate finance services. Continental will dedicate their time and resources to insure a successful outcome for all parties. For more information visit:

Mr. Gary Berthold, CEO of InoLife Technologies, Inc., states, "We are exceptionally pleased by Continental Investment's dedication and confidence in our future. Continental's recognition of InoLife's technical skills and the genetic product market potential will enable us to rapidly increase our current position and jump ahead of our competition."

InoLife Technologies, Inc. is a recognized, reliable and trusted source for state of the art DNA testing products.

InoLife secures their product lines through independent development, licensing and joint venture relationships. Currently InoLife is under an exclusive licensing agreement with InoHealth Products, Inc. ( The Agreement allows InoLife to commercially market specific testing products from InoHealth that includes a DNA Ancestral Origin application, two separate DNA paternity tests, at-home drug test for 12 illicit drugs and a Plavix metabolizing test to name a few.

About InoLife Technologies, Inc.
Positioned for growth and success in a burgeoning market, InoLife Technologies,, is primarily focused on products, services and solutions that will enable state-of-the-art healthcare for today and the future for a diverse base of customers and end-users. The Company's mission is to identify, develop, integrate and bring to market innovative healthcare-based products and services, which provide timely and practical solutions. The primary products and services that InoLife currently addresses specifically focus on products and services that provide key solutions through the innovative use of specialized DNA testing and genetic analysis systems.

The principal customers for InoLife's products and services are healthcare providers, physicians, practioners, hospitals, and outpatient facilities. InoHealth will be marketing and distributing its proprietary products to a wide variety of customers through e-commerce, direct sales, healthcare providers, distributors and retail sellers including specialty retailers.

Forward-Looking Statements
Safe Harbor Statement under the Private securities Litigation Reform Act of 1995: The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements including, but not limited to, certain delays beyond the Company's control with respect to market acceptance of new technologies, products and services, delays in testing and evaluation of products and services, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.

Contact Information